0947 ET - While D. Boral Capital says Invivyd's guidance didn't include the potential expansion of its Pemgarda drug use, analyst Jason Kolbert says it shows the challenges in securing approvals for COVID-19 therapeutics and reinforces the importance of pipeline diversification to sustain long-term growth. Pemgarda is a monoclonal antibody medication authorized for the pre-exposure prophylaxis of COVID‑19. Kolbert says Invivyd remains engaged with the FDA in pursuit of a regulatory pathway for its medication while preparing to provide additional data and regulatory correspondence to underscore its position. Invivyd tumbles 27% to $1.30. (adriano.marchese@wsj.com)
(END) Dow Jones Newswires
February 24, 2025 09:48 ET (14:48 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.